Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 8/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 8/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 8/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 8/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 8/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 8/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | JUN | P05412 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31318302 | 0.89 | CD274 (0.38) | CD274JAK2JAK1TYK2JAK3 | |
| SCHEMBL31318303 | 0.89 | CD274 (0.38) | CD274JAK2JAK1TYK2JAK3 | |
| SCHEMBL25261220 | 0.88 | JAK2 (0.36) | CD274JAK2JAK1TYK2JAK3 | |
| SCHEMBL23233931 | 0.88 | JAK2 (0.35) | CD274JAK2JAK1TYK2JAK3 | |
| SCHEMBL23209279 | 0.86 | JAK2 (0.42) | JAK2JAK3CDK4CDK2CDK7 | |
| SCHEMBL31423919 | 0.81 | CD274 (0.40) | CD274JAK2JAK1TYK2JAK3 | |
| SCHEMBL24848855 | 0.80 | JAK2 (0.42) | CD274JAK2JAK1TYK2JAK3 | |
| SCHEMBL24848856 | 0.79 | JAK2 (0.42) | CD274JAK2JAK1TYK2JAK3 | |
| SCHEMBL25422687 | 0.78 | JAK2 (0.35) | CD274JAK2JAK1TYK2JAK3 | |
| SCHEMBL23209368 | 0.78 | JAK2 (0.44) | CD274JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192706-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-20230192706-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-20230192706-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192706-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CDK2, CCNI, CDK1 | CD274 2843/4885JAK2 232/4885JAK1 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.